Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Biomarkers and cardiovascular disease: determining causality and quantifying contribution to risk assessment.

Shah SH, de Lemos JA.

JAMA. 2009 Jul 1;302(1):92-3. doi: 10.1001/jama.2009.949. No abstract available.

PMID:
19567447
2.

Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study.

Tsimikas S, Clopton P, Brilakis ES, Marcovina SM, Khera A, Miller ER, de Lemos JA, Witztum JL.

Circulation. 2009 Apr 7;119(13):1711-9. doi: 10.1161/CIRCULATIONAHA.108.836940. Epub 2009 Mar 23.

3.

Monocyte-endothelial cell interactions in the development of atherosclerosis.

Mestas J, Ley K.

Trends Cardiovasc Med. 2008 Aug;18(6):228-32. doi: 10.1016/j.tcm.2008.11.004. Review.

4.

Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study.

Brilakis ES, Khera A, Saeed B, Banerjee S, McGuire DK, Murphy SA, de Lemos JA.

Clin Chem. 2008 Dec;54(12):1975-81. doi: 10.1373/clinchem.2008.107359. Epub 2008 Oct 2.

5.

The association between peptidoglycan recognition protein-1 and coronary and peripheral atherosclerosis: Observations from the Dallas Heart Study.

Rohatgi A, Ayers CR, Khera A, McGuire DK, Das SR, Matulevicius S, Timaran CH, Rosero EB, de Lemos JA.

Atherosclerosis. 2009 Apr;203(2):569-75. doi: 10.1016/j.atherosclerosis.2008.07.015. Epub 2008 Jul 25.

PMID:
18774573
6.

The association between plasma caspase-3, atherosclerosis, and vascular function in the Dallas Heart Study.

Matulevicius S, Rohatgi A, Khera A, Das SR, Owens A, Ayers CR, Timaran CH, Rosero EB, Drazner MH, Peshock RM, de Lemos JA.

Apoptosis. 2008 Oct;13(10):1281-9. doi: 10.1007/s10495-008-0254-1.

PMID:
18763039
7.

Variable contributions of fat content and distribution to metabolic syndrome risk factors.

Grundy SM, Adams-Huet B, Vega GL.

Metab Syndr Relat Disord. 2008 Dec;6(4):281-8. doi: 10.1089/met.2008.0026.

8.

Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.

Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.

Arthritis Rheum. 2008 Aug;58(8):2257-67. doi: 10.1002/art.23667.

9.

Differential expression of cytokines, chemokines and chemokine receptors in patients with coronary artery disease.

de Oliveira RT, Mamoni RL, Souza JR, Fernandes JL, Rios FJ, Gidlund M, Coelho OR, Blotta MH.

Int J Cardiol. 2009 Jul 24;136(1):17-26. doi: 10.1016/j.ijcard.2008.04.009. Epub 2008 Jul 9.

PMID:
18617279
10.

Chemokines in atherosclerosis: an update.

Zernecke A, Shagdarsuren E, Weber C.

Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1897-908. doi: 10.1161/ATVBAHA.107.161174. Epub 2008 Jun 19. Review.

11.

A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins.

Breland UM, Halvorsen B, Hol J, Øie E, Paulsson-Berne G, Yndestad A, Smith C, Otterdal K, Hedin U, Waehre T, Sandberg WJ, Frøland SS, Haraldsen G, Gullestad L, Damås JK, Hansson GK, Aukrust P.

Arterioscler Thromb Vasc Biol. 2008 May;28(5):1005-11. doi: 10.1161/ATVBAHA.108.162305. Epub 2008 Feb 14.

12.

Growth-related oncogene-alpha induces endothelial dysfunction through oxidative stress and downregulation of eNOS in porcine coronary arteries.

Bechara C, Wang X, Chai H, Lin PH, Yao Q, Chen C.

Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H3088-95. Epub 2007 Sep 14.

13.

Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease.

Ardigo D, Assimes TL, Fortmann SP, Go AS, Hlatky M, Hytopoulos E, Iribarren C, Tsao PS, Tabibiazar R, Quertermous T; ADVANCE Investigators.

Physiol Genomics. 2007 Nov 14;31(3):402-9. Epub 2007 Aug 14.

14.

Sequential patterns of chemokine- and chemokine receptor-synthesis following vessel wall injury in porcine coronary arteries.

Jabs A, Okamoto E, Vinten-Johansen J, Bauriedel G, Wilcox JN.

Atherosclerosis. 2007 May;192(1):75-84. Epub 2006 Aug 22.

PMID:
16926016
15.

Prevalence and determinants of troponin T elevation in the general population.

Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, Wians F, Sabatine MS, Morrow DA, de Lemos JA.

Circulation. 2006 Apr 25;113(16):1958-65. Epub 2006 Apr 17.

16.

Influence of eotaxin 67G>A polymorphism on plasma eotaxin concentrations in myocardial infarction survivors and healthy controls.

Sheikine Y, Olsen B, Gharizadeh B, Jatta K, Tornvall P, Ghaderi M.

Atherosclerosis. 2006 Dec;189(2):458-63. Epub 2006 Feb 28.

PMID:
16510147
17.

The many roles of chemokines and chemokine receptors in inflammation.

Charo IF, Ransohoff RM.

N Engl J Med. 2006 Feb 9;354(6):610-21. Review. No abstract available.

PMID:
16467548
18.

Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study.

Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, Wians FH Jr, Grundy SM, McGuire DK.

Circulation. 2006 Jan 3;113(1):38-43. Epub 2005 Dec 27.

19.

Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function.

Browning JL, Allaire N, Ngam-Ek A, Notidis E, Hunt J, Perrin S, Fava RA.

Immunity. 2005 Nov;23(5):539-50.

20.

Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study).

Abdullah SM, Khera A, Das SR, Stanek HG, Canham RM, Chung AK, Morrow DA, Drazner MH, McGuire DK, de Lemos JA.

Am J Cardiol. 2005 Nov 1;96(9):1284-9. Epub 2005 Sep 9.

PMID:
16253599
Items per page

Supplemental Content

Write to the Help Desk